![Drug Utilization and the Pharmaceutical Pipeline: Correctional](http://s1.studyres.com/store/data/008697439_1-2829077ff2f334e8fc7658b694401b8e-300x300.png)
Drug Utilization and the Pharmaceutical Pipeline: Correctional
... • Identify new agents in development and compare them with currently available treatment options by therapeutic class as well as summarize first time generic dates of availability of commonly used agents over the next 24 months. • Assess the impact of new medications and newly approved generic formu ...
... • Identify new agents in development and compare them with currently available treatment options by therapeutic class as well as summarize first time generic dates of availability of commonly used agents over the next 24 months. • Assess the impact of new medications and newly approved generic formu ...
In-vitro susceptibility of Giardia lamblia to albendazole
... These results indicate that the benzimidazole carbamates, albendazole and mebendazole are considerably more active against G. ZambZia P1 than the other test drugs, including the 5-nitroimidazoles ornidazole, tinidazole and metronidazole. Meloni et all3 found that albendazole was 5-10 times more acti ...
... These results indicate that the benzimidazole carbamates, albendazole and mebendazole are considerably more active against G. ZambZia P1 than the other test drugs, including the 5-nitroimidazoles ornidazole, tinidazole and metronidazole. Meloni et all3 found that albendazole was 5-10 times more acti ...
EVALUATION OF ANTIEPILEPTIC AND NOOTROPIC EFFECTS OF
... of Rosemary (Rosmarinus officinalis L.) and they concluded that rosemary extract were a stronger inhibitory effect on the bacteria. Minimum inhibitory concentration values for both bacteria Leuconostoc mesenteroides and Lactobacillus delbruekiiranged between 1. 5 mg/ml and 1.75 mg/ml29. 2. Hari Om S ...
... of Rosemary (Rosmarinus officinalis L.) and they concluded that rosemary extract were a stronger inhibitory effect on the bacteria. Minimum inhibitory concentration values for both bacteria Leuconostoc mesenteroides and Lactobacillus delbruekiiranged between 1. 5 mg/ml and 1.75 mg/ml29. 2. Hari Om S ...
Sodium-Glucose Co-transporter 2 Inhibitor: A Perspective on
... producing an osmotic diuresis and some degree of natriuresis. The Food and Drug Administration (FDA) has thus far approved three drugs of this class for the treatment of type 2 diabetes – empagliflozin, canagliflozin, and dapagliflozin. Review results: During the clinical trials performed to establi ...
... producing an osmotic diuresis and some degree of natriuresis. The Food and Drug Administration (FDA) has thus far approved three drugs of this class for the treatment of type 2 diabetes – empagliflozin, canagliflozin, and dapagliflozin. Review results: During the clinical trials performed to establi ...
Antimycobacterial Drugs (抗分枝杆菌药)
... active against atypical mycobacteria. Moxifloxacin is the most active against M tuberculosis by weight in vitro. Levofloxacin tends to be slightly more active than ciprofloxacin against M tuberculosis, ciprofloxacin is slightly more active against atypical mycobacteria. Fluoroquinolones are an impor ...
... active against atypical mycobacteria. Moxifloxacin is the most active against M tuberculosis by weight in vitro. Levofloxacin tends to be slightly more active than ciprofloxacin against M tuberculosis, ciprofloxacin is slightly more active against atypical mycobacteria. Fluoroquinolones are an impor ...
Sialic acids in biological and therapeutic processes
... stimulating hormone (FSH) and human chorionic gonadotropin (hCG), contributes to their stability and functionality.[15] The following sections provide a more in-depth discussion of the roles of sialic acid containing carbohydrates in specific biological pathways, to highlight the opportunities and c ...
... stimulating hormone (FSH) and human chorionic gonadotropin (hCG), contributes to their stability and functionality.[15] The following sections provide a more in-depth discussion of the roles of sialic acid containing carbohydrates in specific biological pathways, to highlight the opportunities and c ...
PPT - ACoP7
... Modeling and simulation (M&S) was employed to recommend doses for human Phase I studies of a direct Factor Xa (FXa) inhibitor, CS-3030. Predicted human pharmacokinetics (PK), biomarker responses (PD), and clinical outcomes were obtained using appropriate projection methods and PK/PD data from cynomo ...
... Modeling and simulation (M&S) was employed to recommend doses for human Phase I studies of a direct Factor Xa (FXa) inhibitor, CS-3030. Predicted human pharmacokinetics (PK), biomarker responses (PD), and clinical outcomes were obtained using appropriate projection methods and PK/PD data from cynomo ...
(HMG-CoA) Reductase Inhibitors
... 60 mg once daily at bedtime concurrent administration with gemfibrozil, other fibrates, lipidlowering doses of niacin, amiodarone, or verapamil: 20 mg once daily at bedtime 4 mg once daily 80 mg once daily concurrent administration with immunosuppressives: 20 mg once daily 40 mg once daily concurren ...
... 60 mg once daily at bedtime concurrent administration with gemfibrozil, other fibrates, lipidlowering doses of niacin, amiodarone, or verapamil: 20 mg once daily at bedtime 4 mg once daily 80 mg once daily concurrent administration with immunosuppressives: 20 mg once daily 40 mg once daily concurren ...
Structural analysis of histamine receptors and its application in drug
... We analyzed the applicability of six hH4R models developed by different methodologies for virtual screening by enrichment tests. We found that different inactive sets have only marginal effect on the highest achievable enrichment factors. On the other hand, the ligand used for optimizing the recepto ...
... We analyzed the applicability of six hH4R models developed by different methodologies for virtual screening by enrichment tests. We found that different inactive sets have only marginal effect on the highest achievable enrichment factors. On the other hand, the ligand used for optimizing the recepto ...
Positioning of HIV-protease inhibitors in clinical practice
... to error. On average, 10 billion HIV particles are produced and cleared every day, with one new mutation introduced, on average, in each new virus genome (mutation rate of 10-4) in the untreated patient3,4. Antiretroviral drugs by themselves do not cause resistance, but provide the selective pressur ...
... to error. On average, 10 billion HIV particles are produced and cleared every day, with one new mutation introduced, on average, in each new virus genome (mutation rate of 10-4) in the untreated patient3,4. Antiretroviral drugs by themselves do not cause resistance, but provide the selective pressur ...
Class Update: Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
... There was a nonsignificant increase in the rate of nonfatal strokes in empagliflozin‐treated patients, which warrants further investigation.1 An FDA analysis reported higher incidence of nonfatal stroke with canagliflozin, another SGLT2 inhibitor, compared to controls (HR 1.46; 95% CI 0.83 to 2.58) ...
... There was a nonsignificant increase in the rate of nonfatal strokes in empagliflozin‐treated patients, which warrants further investigation.1 An FDA analysis reported higher incidence of nonfatal stroke with canagliflozin, another SGLT2 inhibitor, compared to controls (HR 1.46; 95% CI 0.83 to 2.58) ...
Carbonic Anhydrase Inhibitors and Activators: Small
... the mere existence of such a class of CA activity modulators. This topic, then, received little attention from the scientific community for at least two reasons: (i) the statement by Clark and Perrin (1951) that activators of CA do not exist and (ii) the idea that the reported activation is not a ph ...
... the mere existence of such a class of CA activity modulators. This topic, then, received little attention from the scientific community for at least two reasons: (i) the statement by Clark and Perrin (1951) that activators of CA do not exist and (ii) the idea that the reported activation is not a ph ...
Hepatitis C Virus Direct-Acting Antiviral Drug Interactions - IAS-USA
... and coadministration results in an approximately 6-fold increase in simeprevir exposure; therefore, coadministration of cyclosporine and imeprevir is not recommended. Coadministration of simeprevir and tacrolimus results in a small increase in simeprevir exposure and a small decrease in tacrolimus e ...
... and coadministration results in an approximately 6-fold increase in simeprevir exposure; therefore, coadministration of cyclosporine and imeprevir is not recommended. Coadministration of simeprevir and tacrolimus results in a small increase in simeprevir exposure and a small decrease in tacrolimus e ...
- International Journal of Advanced Biological and
... Shirazi M.H. et al. had studied the in vitro inhibitory effects of G. glabra extract against the growth of Salmonella typhi, S. paratyphi B, Shigella sonnei, S. flexneri and enterotoxigenic E. coli (ETEC E. coli) was investigated using well and disc diffusion method. Salmonella paratyphi B showed no ...
... Shirazi M.H. et al. had studied the in vitro inhibitory effects of G. glabra extract against the growth of Salmonella typhi, S. paratyphi B, Shigella sonnei, S. flexneri and enterotoxigenic E. coli (ETEC E. coli) was investigated using well and disc diffusion method. Salmonella paratyphi B showed no ...
Medicines Management Programme: Preferred Medicines Angiotensin‐Converting Enzyme Inhibitors
... therapeutic indications. As the focus of this guidance is the use of ACE inhibitors for hypertension and heart failure, the preferred ACE inhibitor should be licensed at minimum for these two indications. Additional licensed therapeutic indications incorporating other patie ...
... therapeutic indications. As the focus of this guidance is the use of ACE inhibitors for hypertension and heart failure, the preferred ACE inhibitor should be licensed at minimum for these two indications. Additional licensed therapeutic indications incorporating other patie ...
Renal failure
... • fatigue, lethargy, and confusion; resolved several days after discontinuing acetazolamide [Schwenk MH, et al. Pharmacotherapy 1995] ...
... • fatigue, lethargy, and confusion; resolved several days after discontinuing acetazolamide [Schwenk MH, et al. Pharmacotherapy 1995] ...
Probing the mechanism of the bifunctional enzyme
... inhibitor ⁄ product, as well as to several amino acid side-chains and water molecules. Secondly, most of the active site is very polar, consisting of four glutamate residues (E311, E319, E492 and E496) and one each of a histidine (H226), a lysine (K252), an aspartate (D315) and a serine (S518). Only ...
... inhibitor ⁄ product, as well as to several amino acid side-chains and water molecules. Secondly, most of the active site is very polar, consisting of four glutamate residues (E311, E319, E492 and E496) and one each of a histidine (H226), a lysine (K252), an aspartate (D315) and a serine (S518). Only ...
COX 2 Inhibitors: New Non-Steroidal Anti
... mediated primarily through inhibition of cyclooxygenase (COX) and prevention of subsequent formation of prostaglandins and related inflammatory mediators. They are one of the most widely used class of drugs and commonest cause of adverse gastrointestinal events resulting in substantial morbidity and ...
... mediated primarily through inhibition of cyclooxygenase (COX) and prevention of subsequent formation of prostaglandins and related inflammatory mediators. They are one of the most widely used class of drugs and commonest cause of adverse gastrointestinal events resulting in substantial morbidity and ...
5-HIV-Pharmacotherapy-Update-2016-no
... results in production of immature, non-infections virus particles. • Occurs post-translation, so PIs are active in acutely and chronically infected cells • High barrier to resistance • Strong CYP 3A4 inhibitors • Many drug interactions • Most require pharmacokinetic “boosting” with ritonavir or cobi ...
... results in production of immature, non-infections virus particles. • Occurs post-translation, so PIs are active in acutely and chronically infected cells • High barrier to resistance • Strong CYP 3A4 inhibitors • Many drug interactions • Most require pharmacokinetic “boosting” with ritonavir or cobi ...
Kaprex® Tetrase™-Based Softgels by Oral
... targeting inhibition of cyclooxygenase gene induction instead of direct cyclooxygenase enzyme inhibition, resulting in an anti-inflammatory with low-predicted GI toxicity. Presented ...
... targeting inhibition of cyclooxygenase gene induction instead of direct cyclooxygenase enzyme inhibition, resulting in an anti-inflammatory with low-predicted GI toxicity. Presented ...
Relative Potency of Protease Inhibitors in Monocytes/Macrophages
... highly effective in a number of clinical trials, with plasma HIV-1 frequently becoming undetectable by RNA polymerase chain reaction [11, 12, 19, 20]. Such potent inhibition of HIV1 replication has also been found to be associated with a decrease in the rate of development of HIV-1 resistance [21]. ...
... highly effective in a number of clinical trials, with plasma HIV-1 frequently becoming undetectable by RNA polymerase chain reaction [11, 12, 19, 20]. Such potent inhibition of HIV1 replication has also been found to be associated with a decrease in the rate of development of HIV-1 resistance [21]. ...
The Efficacy of Synthetic Steroids to Inhibit Hormonal
... polarization assays compare affinities of 19nortestosterone derivatives. Greater the side chain length = greater affinity ...
... polarization assays compare affinities of 19nortestosterone derivatives. Greater the side chain length = greater affinity ...